Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Roivant in talks to sell bowel disease drug to Roche in over $7 billion deal - WSJ

Published 07/13/2023, 06:27 PM
Updated 07/14/2023, 04:15 AM
© Reuters. FILE PHOTO: A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012.    REUTERS/Michael Buholzer/File Photo

(Reuters) -Biotech company Roivant Sciences is in talks to sell an experimental drug to treat inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, to Roche in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday.

The sale of the drug could be announced in the coming days, the report said citing people familiar with the matter. The talks could still fall apart and another suitor could swoop in, it added.

Shares of Roivant rose 12.8% in extended trade.

Roivant's experimental drug, RVT-3101, is under clinical trials for the treatment of moderate-to-severe ulcerative colitis, a long-term condition where the colon and rectum become inflamed, as well as a type of inflammatory bowel disease known as Crohn's disease.

© Reuters. FILE PHOTO: A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012.    REUTERS/Michael Buholzer/File Photo

RVT-3101 showed improvement in inflammation and ulcers in the colon when compared to a placebo in a mid-stage study in June.

Roivant and Roche declined to comment on the matter.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.